EAU Upgrades Aquablation Therapy to 'Strong' Recommendation for BPH Treatment

关键事实

1The European Association of Urology (EAU) upgraded Aquablation therapy to a "Strong Surgical Recommendation" for treating Benign Prostatic Hyperplasia (BPH).

2The update reflects growing clinical evidence supporting the efficacy of the robotic waterjet therapy.

The European Association of Urology (EAU) has officially upgraded its clinical guidelines to provide a 'Strong Surgical Recommendation' for Aquablation therapy. Developed by PROCEPT BioRobotics (PRCT), Aquablation is a robotic-assisted, waterjet-based treatment for Benign Prostatic Hyperplasia (BPH). The upgrade is supported by a robust body of clinical data demonstrating the therapy's safety and efficacy compared to traditional surgical methods. This regulatory milestone is expected to significantly accelerate clinical adoption and streamline insurance reimbursement processes across Europe. Analysts view this development as a major catalyst for PROCEPT BioRobotics, likely driving long-term revenue growth. The EAU's endorsement underscores the increasing shift toward robotic-assisted medical solutions in the urology sector.

免费注册以访问此内容

创建免费账户